Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

FDA grants priority review for Exelixis’ Cabometyx to treat advanced RCC

pharmaceufical-technologyOctober 19, 2017

Tag: FDA , Exelixis , Cabometyx , RCC

PharmaSources Customer Service